NSE/EXPLEOSOL

EXPLEOSOLEXPLEOSOL

NSE Equity · NSE

₹833.2+5.88%

52-wk low52-WEEK RANGE52-wk high

₹646.9+28.8% from low ·-37.5% from high₹1,333

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

EXPLEOSOL+5.54% · 1Y

Range high ₹1,370.9Range low ₹640Latest ₹833.2252 bars · daily-close · NSE bhavcopy + 10Y history

NSE EquityInformation Technology ServicesSmallcapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite63/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return -6.4% — underperformer
· Below 200-DMA (-14.1%) — downtrend

Valuation

Low

Appears to be fairly valued to cheap vs peers.

· P/E 12.2 vs sector median 24.8 — 51% cheaper
· P/B 1.84 below sector median 2.26

Growth

High

Growing faster than the broader market.

· 3Y revenue CAGR +53.6% — consistent compounder

Profitability

Medium

Average profitability vs peers.

· ROE 15.1%
· Net margin 0.0% — loss-making

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeA(75/100)

Durability

83/100

Financially resilient — strong quality + solvency profile.

Show 2 drivers

Debt/Equity0.03 (100pt)
ROE15.1% (60pt)

Valuation

A+

91/100

Attractively valued vs peers and growth — good margin of safety.

Show 4 drivers

P/E vs sector (12.2 / 24.8)49% (100pt)
P/B1.84 (70pt)
Dividend yield5.67% (100pt)
EV/EBITDA6.0 (90pt)

Momentum

50/100

Momentum is muted; trend is unclear or rolling over.

Show 5 drivers

52w change-6.4% (37pt)
DMA-trend alignmentsideways (50pt)
RSI (14)66.2 (89pt)
Price vs 200-DMA-15.7% (29pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)12.18

UNDERVALUED

CheapestP/E 12.2 at 13th %ile of sector — cheaper than 87% of peers.Most expensive

P/B1.84

FAIR

CheapestP/B 1.84 at 37th %ile of sector.Most expensive

EV/EBITDA5.98

UNDERVALUED

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: Jun +8.39% · Worst: Mar -7.67%

Jan

-1.2%

40% win

Feb

-4.9%

40% win

Mar

-7.7%

30% win

Apr

+5.7%

70% win

May

+4.2%

50% win

Jun

+8.4%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+1.28%

Median

+0.00%

Std dev

14.75%

Best

+79.9%

Worst

-46.0%

% positive

48%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 3

Lean balance sheet (D/E 0.03)
Low leverage means earnings are less sensitive to rate cycles
Consistent top-line growth (53.6% 3Y CAGR)
Sustained revenue compounding is rare and hard to fake
Top quartile ROE in Other
Rank 229 of 1000 peers

WEAKNESSES · 0

No material weaknesses flag from the numbers

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+5.9%

+10.3%

+14.0%

-14.5%

-15.2%

+3.2%

-13.0%

+9.7%

10Y

+3.5%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
EXPLEOSOLTHIS Expleo Solutions Limited	₹833.2	-6.4%	1,296	12.2	1.84	15.1%	0.03	—
ABCAPITAL Aditya Birla Capital Limited	₹340.4	+68.1%	89,888	25.8	2.79	10.8%	4.60	+17.6%
ABBOTINDIA Abbott India Limited	₹25,785	-16.6%	54,547	35.8	13.60	38.0%	0.04	+9.6%
360ONE 360 ONE WAM LIMITED	₹1,113.3	+16.7%	44,744	38.7	4.77	12.3%	1.47	+35.0%
3MINDIA 3M India Limited	₹31,410	+4.4%	35,158	92.9	21.83	23.5%	0.06	+6.1%
AADHARHFC Aadhar Housing Finance Limited	₹496.45	+3.5%	21,173	20.8	3.05	14.6%	2.55	—
ABDL Allied Blenders and Distillers Limited	₹573.8	+76.4%	16,176	60.4	10.70	17.7%	0.67	+5.8%
AAVAS Aavas Financiers Limited	₹1,347.9	-37.8%	10,612	17.1	2.26	13.3%	3.08	+13.3%
63MOONS 63 moons technologies limited	₹662.7	-9.8%	8,006	—	0.92	-0.2%	0.00	-6.3%

ASK AXEL

Dig deeper into EXPLEOSOL

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for EXPLEOSOL — all in one sourced reply.

Ask free in chat

Run these tools on EXPLEOSOL

Historical return →

"If I had bought EXPLEOSOL in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on EXPLEOSOL

Brokerage + charges →

All-in cost for trading EXPLEOSOL

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Date	Amount
2025-02-12	₹50.00
2023-07-14	₹5.00
2018-07-19	₹20.00
2017-11-09	₹4.00
2017-07-20	₹20.00
2016-11-03	₹4.00
2016-07-21	₹20.00

EXPLEOSOLEXPLEOSOL

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Company + balance sheet snapshot

Peer comparison · Other

Ask Axel about EXPLEOSOL

Recent news

Dig deeper into EXPLEOSOL

Run these tools on EXPLEOSOL

Technical snapshot

Dividends + splits history

Stock scorecard

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Company + balance sheet snapshot

Recent news

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Peer comparison · Other